Cadrenal <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter net loss of $2.7 million
Cadrenal Therapeutics Inc. reported a net loss of $2.7 million for the third quarter ended September 30, 2025, compared to a net loss of $2.4 million for the same period in 2024. Research and development expenses were $0.7 million, down from $0.8 million in the prior year, while general and administrative expenses increased to $2.0 million from $1.7 million. The company held $3.9 million in cash and cash equivalents as of September 30, 2025, with approximately 2.1 million shares of common stock outstanding. During the quarter, Cadrenal completed manufacturing of the tecarfarin drug product in accordance with current good manufacturing practices, advanced clinical activities for tecarfarin in LVAD and dialysis patients, and expanded its portfolio through the acquisition of eXIthera Pharmaceuticals' investigational Factor XIa inhibitor assets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-107949), on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.